Urogen Pharma Ltd.

University of California

Omer Tsipori

Marina Konorty

Yulia Hionidi

Ralph V Clayman

Mark Schoenberg

Pengbo Jiang

A kit provides for sustained release of therapeutic agents for local treatment of cancer diseases by providing lyophilized Mitomycin C in a slowly releasing biocompatible hydrogel to be applied to affected tissue. The hydrogel comprises poloxamer 407, hydroxypropylmethylcellulose and water. A lyophilized composition comprises mitomycin C and urea as a bulking agent.

Material and method for treating cancer

Pharmaceutical compositions and methods for sustained release of therapeutic agents for local treatment of cancer diseases involve embedding lyophilized mitomycin C in a slowly releasing biocompatible hydrogel applied to affected tissue. The mitomycin C is lyophilized in a composition using urea as a bulking agent, and the mitomycin C and the bulking agent are present in a ratio of from about 1:7 to about 1:9 in the lyophilized pharmaceutical composition.

Provided herein are methods for treating nephrolithiasis and protecting the urothelium and inner lining of the kidney from thermal damage during lithotripsy by use of a thermosensitive bio-adhesive hydrogel. The described method dramatically improved the efficiency and effectiveness of stone clearance compared to conventional techniques while providing protection to the urothelium from potentially damaging temperature spikes.

Growing community of inventors

Shaar Efraim, Israel

Omer Tsipori